IL ‐17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL‐25‐Driven Intestinal Inflammation

ConclusionIn a subgroup of SpA patients, the initiation of IL ‐17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notablyC. albicans. Further, IL ‐17i‐related CD was associated with overexpression of IL‐25/IL‐17E‐producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL‐17 pathway and the (sub)clinical gut inflammation observed in SpA.

Source: Arthritis and Rheumatology - November 13, 2019 Category: Rheumatology Authors: Julia Manasson, David S. Wallach, Giuliana Guggino, Matthew Stapylton, Michelle H. Badri, Gary Solomon, Soumya M. Reddy, Roxana Coras, Alexander A. Aksenov, Drew R. Jones, Parvathy V. Girija, Andrea L. Neimann, Adriana Heguy, Leopoldo N. Sega Tags: Full Length Source Type: research